newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - VAXCYTE INC

  • Explicit Guidance:

    • BLA Filing Timeline: Submission for Vax31 in adults expected in the first half of 2028; no specific revenue or earnings guidance provided for FY2029 or FY2030.
    • Infant Data Readout: Full Phase 2 data for Vax31 in infants expected by the end of the first half of 2026.
    • Clinical Study Milestones: Two additional pivotal adult Phase 3 studies (Opus 2 and Opus 3) expected to read out in the first half of 2026; manufacturing consistency study (CMC) expected to launch in 2027 with results timed for the 2028 filing.
  • Business-Segment Outlook:

    • Adult Pneumococcal Market (Vax31): Targeting a global adult market currently valued at $2.5–$3 billion (one-third of the $8–$8.5 billion total market), expected to grow to ~$6 billion (half of a projected $12+ billion total global market) within 5–6 years.
    • Launch Ramp-up: Anticipates rapid market share acquisition similar to historical PCV launches (e.g., Capvaxiv capturing >45% market share in its first 12 months), driven by expansion from 20-valent to broader serotype coverage.
    • Infant Market: Positioning Vax31 to cover 90%+ of circulating infant disease strains versus ~60% for Prevnar 20; leveraging higher doses to improve immune responses compared to predecessor Vax24.
    • Revaccination Opportunity: Seeking data and recommendations to support revaccination for adults previously immunized with PCV13/20/21, potentially unlocking a significant addressable patient population as the market shifts from one-dose to multi-dose strategies.
  • Market and Competitive Outlook:

    • Competitive Landscape: Expecting the market to favor broader serotype coverage over specific serotype 3 immunogenicity, citing Pfizer's Prevnar 20 capturing >90% market share despite lower serotype 3 response than Merck's VaxNeuvance (15-valent).
    • Commercial Distribution: Targeting ~200 key accounts in the U.S. (retail pharmacies like CVS/Walgreens and large health systems) which comprise >75% of adult immunization; contracts expected to have "innovation clauses" allowing immediate inclusion upon licensure.
    • Serotype 3 Dynamics: Acknowledged as a "recalcitrant" serotype that eludes antibody clearance; noted that higher antibody responses to Serotype 3 by competitors have not translated to clinical or commercial benefit to date.
    • Global Expansion: Anticipates Europe and international markets coming online with adult recommendations, shifting the global mix from 1/3 adult / 2/3 infant today to roughly 50/50 split in the future.
  • Macro / Industry Outlook:

    • Regulatory Environment: Expresses confidence in non-ACIP recommending bodies (AMA, Vaccine Integrity Project, AAFP) coordinating to ensure vaccination coverage recommendations and health coverage exist, noting these efforts have been "pleasantly surprised" and "very coordinated" during the recent influenza season.
    • ACIP Dynamics: Anticipates ACIP will revisit revaccination recommendations specifically in the context of Vax31's approval, leveraging the precedent set by the lowering of the initial vaccination age to 50.
  • Strategic Initiatives:

    • Manufacturing & Capacity: Current consistency study will utilize materials from Lonza's multi-use facility; a second facility is fully operational but will be unlocked for commercial use in a follow-on effort post-launch.
    • Pipeline Progress: Advancing Group A Strep vaccine (novel, "blockbuster opportunity" white space) alongside the lead Vax31 program.
    • Commercial Team: Chief Commercial Officer (Mike Mullet) hired to lead U.S. and global launches, bringing experience from Sanofi and Moderna vaccine introductions.
    • Submission Strategy: Base case is a "one fell swoop" BLA filing; rolling submission remains an option but not currently pursued.
    • Data Release Strategy: Leaning toward a concurrent unblinding of primary series and booster data for the infant program by early 2026, pending confirmation of operational benefits from sequential release.
  • Risks and Headwinds to Outlook:

    • Regulatory Delays: Dependence on ACIP and other recommending bodies for approval recommendations; current ACIP functionality noted as not operating as in the past.
    • Clinical Non-Inferiority: Acknowledges that expanding from 20 to 31 valencies may result in "non-inferiority misses" for overlapping serotypes, though high confidence exists that incremental 11 serotypes will clear thresholds.
    • Serotype 3 Efficacy: Uncertainty regarding whether higher serotype 3 responses by competitors (e.g., Pfizer's 25-valent) will eventually translate to clinical benefit, though currently viewed as not differentiating.
    • Operational Timing: Potential risk to the 2028 filing timeline if manufacturing consistency study results or regulatory reviews extend beyond expectations.
  • Management Tone on the Future:

    • Confidence Level: High confidence in the "rousing success" of adult pivotal data and the "strong start" of the pipeline; describes the adult launch opportunity as "very advantageous."
    • Strategic Hedges: Management explicitly states they are not guiding to revenue figures yet, deferring to historical benchmarks for market share speed.
    • Differentiation Strategy: Emphasizes "totality" of the product profile (broader coverage + higher dose) over narrow immunogenicity metrics for specific serotypes (e.g., Serotype 3), betting on market behavior favoring broader coverage.
    • Growth Narrative: Strong optimism regarding the structural growth of the adult immunization market, viewing the shift to higher-valent vaccines as a primary driver of value expansion over the next 5–6 years.
  • Miscellaneous:

    • Market Sizing: Global PCV market projected to grow from $8.5 billion today to $12 billion+ by 2030/2031, driven primarily by adult indications.
    • Commercial Precedents: Cites Capvaxiv's 45% market share in year one as a benchmark for Vax31's potential uptake speed in the U.S. retail and health system channels.
Company
VAXCYTE INC
Keywords
VAXCYTE INC